Lisata Therapeutics to Present at the Investival Showcase USA
Lisata Therapeutics, a clinical-stage pharmaceutical company focused on therapies for advanced solid tumors and other serious diseases, announced that its President and CEO, David J. Mazzo, Ph.D., will present at the Investival Showcase USA. The event is scheduled for March 10-11, 2025, in Miami, Florida.
Dr. Mazzo's presentation will occur on March 11th at 11:30 a.m. Eastern Time. For more information about the conference and registration details, please click here.
Lisata Therapeutics, un'azienda farmaceutica in fase clinica focalizzata su terapie per tumori solidi avanzati e altre malattie gravi, ha annunciato che il suo Presidente e CEO, David J. Mazzo, Ph.D., presenterà all'Investival Showcase USA. L'evento è programmato per 10-11 marzo 2025, a Miami, Florida.
La presentazione del Dr. Mazzo avrà luogo il 11 marzo alle 11:30 ora orientale. Per ulteriori informazioni sulla conferenza e sui dettagli di registrazione, si prega di cliccare qui.
Lisata Therapeutics, una compañía farmacéutica en etapa clínica centrada en terapias para tumores sólidos avanzados y otras enfermedades graves, anunció que su Presidente y CEO, David J. Mazzo, Ph.D., presentará en el Investival Showcase USA. El evento está programado para 10-11 de marzo de 2025, en Miami, Florida.
La presentación del Dr. Mazzo se llevará a cabo el 11 de marzo a las 11:30 a.m. hora del Este. Para más información sobre la conferencia y detalles de registro, por favor haga clic aquí.
리사타 테라퓨틱스, 고급 고형 종양 및 기타 심각한 질병을 위한 치료제에 중점을 둔 임상 단계 제약 회사는 데이비드 J. 마조, Ph.D.가 인베스티벌 쇼케이스 USA에서 발표할 것이라고 발표했습니다. 이 행사는 2025년 3월 10-11일에 플로리다주 마이애미에서 열릴 예정입니다.
마조 박사의 발표는 3월 11일 오전 11시 30분 동부 표준시에 진행될 예정입니다. 컨퍼런스 및 등록 세부정보에 대한 추가 정보는 여기를 클릭하십시오.
Lisata Therapeutics, une entreprise pharmaceutique en phase clinique axée sur les thérapies pour les tumeurs solides avancées et d'autres maladies graves, a annoncé que son Président et CEO, David J. Mazzo, Ph.D., fera une présentation lors de l'Investival Showcase USA. L'événement est prévu pour le 10-11 mars 2025, à Miami, en Floride.
La présentation du Dr Mazzo aura lieu le 11 mars à 11h30, heure de l'Est. Pour plus d'informations sur la conférence et les détails d'inscription, veuillez cliquer ici.
Lisata Therapeutics, ein klinisch tätiges Pharmaunternehmen, das sich auf Therapien für fortgeschrittene solide Tumore und andere schwere Krankheiten konzentriert, gab bekannt, dass sein Präsident und CEO, David J. Mazzo, Ph.D., auf dem Investival Showcase USA präsentieren wird. Die Veranstaltung ist für 10.-11. März 2025 in Miami, Florida, angesetzt.
Die Präsentation von Dr. Mazzo findet am 11. März um 11:30 Uhr Eastern Time statt. Für weitere Informationen zur Konferenz und zur Registrierung klicken Sie bitte hier.
- None.
- None.
BASKING RIDGE, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present a corporate overview at the Investival Showcase USA, taking place March 10-11, 2025 in Miami, Florida.
Dr. Mazzo’s presentation is scheduled for Tuesday, March 11th at 11:30 a.m. Eastern Time. For more information about the conference, including registration details, please click here.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into the second quarter of 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. Learn more about certepetide’s mechanism of action in our short film. For more information on the Company, please visit www.lisata.com.
Lisata Therapeutics Contact:
Investors:
Lisata Therapeutics
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Media:
ICR Healthcare
Elizabeth Coleman
Account Supervisor
Phone: 203-682-4783
Email: elizabeth.coleman@icrhealthcare.com
This press release was published by a CLEAR® Verified individual.
FAQ
What is Lisata Therapeutics presenting at the Investival Showcase USA?
When is Lisata Therapeutics presenting at the Investival Showcase USA?
Where is the Investival Showcase USA taking place?
Who will present on behalf of Lisata Therapeutics at the Investival Showcase USA?
What is the focus of Lisata Therapeutics' presentation at the Investival Showcase USA?
When is the Investival Showcase USA scheduled?
